Mpox Cases Among Cisgender Women and Pregnant Persons — United States, May 11–November 7, 2022
Lisa P. Oakley, Kaitlin Hufstetler, Jesse O’Shea, J. Danielle Sharpe, Cristin E. McArdle, Varsha Neelam, Nicole M. Roth, Emily O’Malley Olsen, Maren Wolf, Leah Zilversmit Pao, Jeremy A.W. Gold, Karlotta M. Davis, Dana Perella, Shara Epstein, Maura K. Lash, Olivia Samson, Jessica Pavlick, Amanda Feldpausch, Jennifer Wallace, Atmaram Nambiar, Van A. Ngo, Umme‐Aiman Halai, Claudia W. Richardson, Traci Fowler, Burnestine P. Taylor, Joyce Chou, Lindsey Brandon, Rose Devasia, Erin K. Ricketts, Catherine Stockdale, Mellisa Roskosky, Rachel Ostadkar, Yeng Vang, Romeo R. Galang, Kiran M. Perkins, Melanie Taylor, Mary Joung Choi, Paul J. Weidle, Patrick Dawson, Sascha Ellington, CDC Mpox Analytics Team, CDC Mpox Analytics Team, Cori Dennison, Ian Hennessee, Aspen Riser, LaTweika A.T. Salmon-Trejo, Gail Scogin, Emily Sims, Penelope Strid, Raquel Velazquez‐Kronen, Claire Xu, Carla Zelaya
Abstract
Four pregnant persons required hospitalization for mpox. Eleven pregnant persons received tecovirimat, and no adverse reactions were reported. Continued studies on mpox transmission risks in populations less commonly affected during the outbreak, including cisgender women and pregnant persons, are important to assess and understand the impact of mpox on sexual, reproductive, and overall health.